IOBT Key Statistics, Chart & Performance
The current stock price of IOBT is 0.6394 USD. In the past month the price decreased by -8.22%. In the past year, price decreased by -26.59%.
IOBT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.7 | 395.77B | ||
| AMGN | AMGEN INC | 15.1 | 177.79B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.57B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.98 | 118.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.61B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 796.86 | 53.69B | ||
| INSM | INSMED INC | N/A | 37.34B | ||
| NTRA | NATERA INC | N/A | 34.33B | ||
| BIIB | BIOGEN INC | 10.91 | 26.79B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.05 | 21.65B | ||
| INCY | INCYTE CORP | 16.61 | 20.94B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About IOBT
Company Profile
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Company Info
IO BIOTECH INC
Ole Maaloes Veh 3
COPENHAGEN DK
Employees: 80
Phone: 4570702980
IO BIOTECH INC / IOBT FAQ
What does IO BIOTECH INC do?
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Can you provide the latest stock price for IO BIOTECH INC?
The current stock price of IOBT is 0.6394 USD. The price increased by 4.82% in the last trading session.
Does IOBT stock pay dividends?
IOBT does not pay a dividend.
What is the ChartMill rating of IO BIOTECH INC stock?
IOBT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
Which stock exchange lists IOBT stock?
IOBT stock is listed on the Nasdaq exchange.
When does IO BIOTECH INC (IOBT) report earnings?
IO BIOTECH INC (IOBT) will report earnings on 2026-03-16, after the market close.
Can you provide the short interest for IOBT stock?
The outstanding short interest for IO BIOTECH INC (IOBT) is 2.95% of its float.
IOBT Technical Analysis
IOBT Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IOBT Forecast & Estimates
12 analysts have analysed IOBT and the average price target is 2.51 USD. This implies a price increase of 292.96% is expected in the next year compared to the current price of 0.6394.